Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

Circulation

Volumn 112, Issue 19, 2005, Pages 2980-2985

  Fries, Roland ^a,c   Shariat, Kaveh ^a   Von Wilmowsky, Hubertus ^b   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Klinikum Bad Bramstedt   (Germany)

^c Gotthard Schettler Klinik   (Germany)

Author keywords

Blood flow; Capillaries; Drugs; Microcirculation; Nitric oxide

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; GLYCERYL TRINITRATE; PENTOXIFYLLINE; PROSTAGLANDIN; SILDENAFIL; VASODILATOR AGENT;

ADULT; AGED; ANEMOMETER; ARTICLE; CAPILLARY FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FEMALE; FLOW RATE; HEADACHE; HEAT SENSATION; HUMAN; MALE; MYALGIA; NAUSEA; NOSE MUCOSA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; RELAPSE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VASODILATATION;

ADULT; AGED; BLOOD FLOW VELOCITY; CONNECTIVE TISSUE DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PIPERAZINES; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 27744564115     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.523324     Document Type: Article

References (22)

1. Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ. 1990;301:590-592.
2. Wigley FM. Raynaud's phenomenon. Curr Opin Rheumatol. 1993;5:773-784.
3. Wigley FM. Clinical practice: Raynaud's phenomenon. N Engl J Med. 2002;347:1001-1008.
4. Goldstein I, Lue TF, Padma-Nathan H. Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl J Med. 1998;338:1397-1404.
5. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.
6. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B, Böhm M, Sybrecht GW. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218-1222.
7. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136:515-522.
8. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-428.
9. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp. Ann Intern Med. 2004;141:169-177.
10. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med. 2004;139:871-872.
11. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn HJ, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jimenez SA, White B, Seibold JR, Wigley FM. Scleroderma Clinical Trials Consortium: measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002;46:2410-2420.
12. Stucker M, Baier V. Reuther T, Hoffmann K, Kellam K, Altmeyer P. Capillary blood cell velocity in human skin capillaries located perpendicularly to the skin surface: measured by a new laser Doppler anemometer. Microvasc Res. 1996;52:188-192.
13. Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum. 2003;48:282-283.
14. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
15. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90-94.
16. Thomas GD, Victor RG. Nitric oxide mediates contraction-induced attenuation of sympathetic vasoconstriction in rat skeletal muscle. J Physiol. 1998;506:817-826.
17. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med. 2000;342:1622-1626.
18. Cremers B, Scheler M, Maack C, Wendler O, Schäfers HJ, Südkamp M, Böhm M. Effects of sildenafil (Viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. J Cardiovasc Pharmacol. 2003;41:734-743.
19. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:845-851.
20. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care. 2002;25:1336-1339.
21. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40:1232-1240.
22. Berkels R, Klotz T, Sticht G, Engelmann U, Klaus W. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Cardiovasc Pharmacol. 2001;37:413-421.